Organization

Vigil Neuroscience, Inc.

About

Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil utilizes the tools of modern neuroscience drug development across multiple therapeutic modalities in efforts to develop precision-based therapies to improve the lives of patients and their families.

Overview

Founded 2020
Type Public
Location Cambridge, Massachusetts, USA

Stock

VIGL $8.90 -0.45% $(0.04)

Latest News

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022 Sep 16, 2022 Benzinga Upgrades Morgan Stanley upgraded the previous rating for Alcoa Corp (NYSE:AA) from Equal-Weight to Overweight. Alcoa earned $2.67 in the second quarter, compared to $1.49...
Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know Sep 14, 2022 Zacks Investment Research The consensus price target hints at a 121.3% upside potential for Vigil Neuroscience, Inc. (VIGL). While empirical research shows that this sought-after metric is hardly...
Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference Sep 01, 2022 GlobeNewswire Inc. CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for...
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022 Aug 29, 2022 Benzinga Upgrades According to Argus Research, the prior rating for AstraZeneca PLC (NASDAQ:AZN) was changed from Hold to Buy. For the second quarter, AstraZeneca had an...
How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133% Aug 29, 2022 Zacks Investment Research The consensus price target hints at a 132.7% upside potential for Vigil Neuroscience, Inc. (VIGL). While empirical research shows that this sought-after metric is hardly...